An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Public ClinicalTrials.gov record NCT02257736. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Study identification
- NCT ID
- NCT02257736
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Aragon Pharmaceuticals, Inc.
- Industry
- Enrollment
- 982 participants
Conditions and interventions
Conditions
Interventions
- Abiraterone acetate Drug
- Apalutamide Drug
- Placebo Drug
- Prednisone Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 25, 2014
- Primary completion
- Mar 18, 2018
- Completion
- Dec 30, 2027
- Last update posted
- May 10, 2026
2014 – 2027
United States locations
- U.S. sites
- 46
- U.S. states
- 22
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | La Mesa | California | — | — |
| Not listed | Los Angeles | California | — | — |
| Not listed | Modesto | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | San Francisco | California | — | — |
| Not listed | Santa Barbara | California | — | — |
| Not listed | Aurora | Colorado | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Jensen Beach | Florida | — | — |
| Not listed | Lakeland | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Ocala | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Melrose | Illinois | — | — |
| Not listed | Niles | Illinois | — | — |
| Not listed | Marrero | Louisiana | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Shreveport | Louisiana | — | — |
| Not listed | Auburn | Maine | — | — |
| Not listed | Baltimore | Maryland | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Omaha | Nebraska | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | Johnson City | New York | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Poughkeepsie | New York | — | — |
| Not listed | Syracuse | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Tualatin | Oregon | — | — |
| Not listed | Lancaster | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Myrtle Beach | South Carolina | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Norfolk | Virginia | — | — |
| Not listed | Richmond | Virginia | — | — |
| Not listed | Auburn | Washington | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Spokane | Washington | — | — |
| Not listed | Wenatchee | Washington | — | — |
| Not listed | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 127 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02257736, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 10, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02257736 live on ClinicalTrials.gov.